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The expression pattern of miR-590-3p is a promising diagnostic biomarker for early 
detection of epithelial ovarian cancer 
 
ABSTRACT 
Epithelial ovarian cancer (EOC) is the most common type of ovarian tumors. The 
biomarkers, which are being used for EOC screening, have low sensitivity and specificity 
leading to late diagnosis and high mortality rate. Thus, identification of effective 
biomarkers for early diagnosis of ovarian cancer has become a high priority in research. 
Here we aim to address this problem by studying the expression of a potential molecular 
marker, miR-590-3p, in EOC. We examined the mRNA steady-state levels of various 
acknowledged biomarkers including cancer antigen-125 (CA125) which is being used for 
EOC screening, c-reactive protein (CRP) which expression was correlated with EOC 
stage and paired homeobox 2 gene (PAX2) whose expression is correlated with the 
histological grade to characterize the histo-pathological features of the specimens at the 
molecular level. We examined the expression of miR-590-3p in EOC patients’ serum and 
EOC tissues, using real-time PCR. The levels of circulating miR-590-3p showed to be 
significantly elevated in 84.6% of the EOC patients’ serum, with 76.92% sensitivity and 
85.7% specificity at its optimal cutoff value. Tissue miR-590-3p showed to be 
upregulated in EOC tissues compared to normal ovarian tissues and highly correlated 
with high-grade poorly differentiated EOC. The adoption of the epithelial-mesenchymal 
transition biomarkers was enriched in EOC with high miR-590-3p levels. The potential 
downstream target genes, SOX2, LEF1 and PAX2, were predicted using miRanda and 
Targetscan in silco tools and their expression profiles were in silco examined using 
Oncomine data-mining platform and StarBase Pan-cancer analysis. We examined the 
levels of SOX2, LEF1 and PAX2 at the RNA and the protein levels via semi-quantitative 
PCR and western blot, respectively. Among the investigated potential target genes, only 
PAX2 showed negative correlation with the levels of miR-590-3p in EOC tissues, 
suggesting that miR-590-3p could acquire its role in EOC carcinogenesis through 
regulation of cellular differentiation in EOC. 
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CHAPTER 1 
Introduction 
1.1 Ovarian Cancer 
Ovarian cancer (OVCA) is the most lethal cancer in the female reproductive system 
(Howlader N, 2015). In developing countries, ovarian cancer represents 18.8% of all 
types of gynecological cancers (Jemal et al., 2011). The worldwide ovarian cancer deaths 
in 2008, was estimated to be 140,200 deaths out of 225,500 ovarian cancer cases, with 
54% of the worldwide ovarian cancer deaths and 55% of the worldwide ovarian cancer 
cases found in the developing countries (Jemal et al., 2011). Moreover, the five-year 
survival among ovarian cancer cases is less than 50% (Sankaranarayanan & Ferlay). This 
high mortality is mainly due to the diagnosis of ovarian cancer at advanced stages. About 
70% of the patients are diagnosed at late stages and that is mainly due to the absence of 
effective screening methods (Gang et al., 2012). Thus, OVCA is called the “silent killer”, 
as the symptoms are not very beneficial for diagnosis because they are similar to that of 
gastrointestinal and gynecological disorders (Gang et al., 2012). The most common type 
of ovarian cancer is the epithelial ovarian cancer (EOC) that accounts for about 90% of 
the ovarian cancer cases. EOC is a highly heterogeneous disease and its etiology is still 
not fully understood. 
1.2 Epithelial ovarian cancer 
The origin of EOC and its etiology are not clear and are strongly debated. Early studies 
used to believe that EOC was derived from the mesothelium, which is the ovarian surface 
epithelium, as reviewed by (Dubeau, 2008). Nonetheless, recent studies proposed that 
EOC was originated from müllerian-type tissues (Bast et al., 2009). EOC is classified into 
various histological subtypes, which are serous, mucinous, endometrioid, transitional 
(Brenner), and clear cell, as reviewed by (V. W. Chen et al., 2003). The morphological 
features of the serous type are similar to that of the fallopian tube epithelium. Mucinous 
and endometrioid types have similar morphology to that of the endocervical epithelium 
and endometrium, respectively. The cervix, endometrium and fallopian tubes are 
originated from müllerian-type tissue. Therefore, EOC shows müllerian phenotype, 
supporting that it could be originated from müllerian-derived tissues (Bast et al., 2009). 
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There are three histological grades of EOC based on the degree of tumor cell 
differentiation. Grade-I is characterized by its well-differentiated cellular appearance. 
Grade-II tumor is characterized by having moderately differentiated tumor cells and 
grade-III tumors are made up of poorly differentiated cells. EOC can be classified into 
four stages depending on the degree of the tumor spread. The stage of the tumor can be 
determined by radiologic evaluation and surgically (Heintz et al., 2006). The EOC 
staging is classified based on the International Federation of Gynecology and Obstetrics 
(FIGO) criteria (Heintz et al., 2006). In stage-I tumors, the tumor is limited to the ovaries, 
could be one (IA) or both of the ovaries (IB). Stage-II tumors are more spread involving 
both of the ovaries and uterus (IIA) and could have extension to the pelvic area (IIB/IIC). 
Stage-III tumors involving the ovaries, with confined intra-peritoneal metastases outside 
the pelvis (IIIA/IIIB) and/or extinction to the peritoneal lymph nodes (IIIC). Finally, 
stage-IV tumors spread beyond the ovaries to reach distant organs as the lungs (Heintz et 
al., 2006). 
1.3 Biomarkers and screening methods for ovarian cancer 
1.3.1. Current biomarkers 
Cancer antigen (CA) 125 is the most popular biomarker for ovarian cancer diagnosis. 
CA125 is a glycoprotein that was found to be elevated in the blood of about 80% of EOC 
patients and in only 50% of patients at early stages (Havrilesky et al., 2008; Rosen et al., 
2005). CA125 gives indication to ovarian cancer progression and response to 
chemotherapy. Also, its levels were found to be elevated in benign cases as in pregnancy 
or fibroids. Therefore, CA125 blood test is being used for ovarian cancer diagnosis along 
with vaginal examination and along with other biomarkers, as the Human Epididymal 
Protein 4 (HE4), in order to increase the sensitivity and specificity of the test (Gadducci 
et al., 2009; Gang et al., 2012; Rosen et al., 2005).  
The Human Epididymal Protein 4 (HE4) is a glycoprotein normally expressed in the 
female reproductive system and is elevated in ovarian cancer cases (Ławicki et al., 2013). 
The specificity and sensitivity of HE4 as a biomarker for ovarian cancer is enhanced, 
when used in conjugation with CA125 blood test (Havrilesky et al., 2008; Ławicki et al., 
2013). The use of HE4 along with CA125 can differentiate between benign conditions 
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and ovarian cancer, which can’t be distinguished by CA125 alone (Gang et al., 2012). 
However, their low sensitivity and low specificity necessitate the development of a new 
efficient biomarker.  
1.3.2 MicroRNA potential biomarker 
MicroRNAs (miRNAs) expression and their use as biomarkers for EOC is a promising 
field of study. Circulating miRNAs are remarkably stable and easily detected. The 
dysregulation of extracellular miRNAs was observed in various diseases, including 
cancer. 
1.3.2.a MiRNA biogenesis 
MiRNAs are mainly transcribed by RNA Polymerase II, producing primary miRNA 
transcript (pri-miRNA) (Y. Lee et al., 2004). RNA Polymerase III transcribes certain 
miRNA genes, located within Alu- repetitive elements in chromosome 19 (Borchert et 
al., 2006). Several miRNA genes are located close to each other and are transcribed as 
long polycistronic primary miRNA (pri-miRNA) transcripts (Y. Lee et al., 2004). Pri-
miRNAs are stem-loop transcripts with length from hundreds to thousand of nucleotides 
with poly-adenylated 3’ end, and 5’cap structures (Y. Lee et al., 2002). In the nucleus, the 
pri-miRNA is processed into hairpin-shaped intermediate 60 to 70 nucleotides in length 
called miRNA precursor (pre-miRNA) by microprocessor multi-protein complex 
(Gregory et al., 2004).  The microprocessor complex consists of Drosha nuclear RNase 
III enzyme, a double-stranded RNA-binding protein (dsRBD) called DGCR8/Pasha and 
co-factors, such as RNA helicases and heterogenous nuclear ribo-nucleoproteins 
(hnRNPs). DGCR8/Pasha protein binds to pri-mRNA at the single stranded RNA- double 
stranded RNA junction in order to direct the Drosha RNase III enzyme to cut the strands 
of the stem at the base of the stem loop. Drosha cleavage generates pre-miRNA with 5’ 
mono-phosphate and 2 nucleotides 3’ overhang which is characteristic for RNase III 
cleavage (Y. Lee et al., 2002).  
The pre-miRNA is then transported in the presence of GTP from the nucleus to the 
cytoplasm by exportin-5 that recognizes the 3’overhang (Gregory et al., 2004). The pre-
miRNA undergoes further processing in the cytoplasm by Dicer RNase III enzyme and 
RNA-induced silencing complex (RISC) (Figure 2). RISC complex encompasses the 
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Argonaute 2 (Ago2) protein and the transactivation-responsive RNA-binding protein 
(TRBP). The Ago2 binds to the pre-miRNA and cleaves its 3’end through exo-
nucleolytic trimming and then Dicer induce further cleavage of the Ago2-cleaved pre-
miRNA to generate mature miRNA duplex (Hutvágner et al., 2001). The miRNA mature 
strand is loaded into the RISC complex and guides the miRNA-RISC complex to the 
complementary sequence in the target mRNA. It mainly represses gene expression by 
inducing mRNA degradation through the endonuclease activity of the Ago protein that 
can cleave miRNA-mRNA double stranded complex (Hutvágner & Zamore, 2002) or 
through mRNA destabilization via inducing mRNA deadenylation (Behm-Ansmant et al., 
2006; Wu et al., 2006) or can inhibit the translation of the target mRNA (Nottrott et al., 
2006; Petersen et al., 2006). MiRNA biogenesis encompasses various complexes that 
cleave, export and generate the mature miRNA. They themselves are regulated by diverse 
mechanisms to ensure the proper miRNA regulation. Each step in the miRNA biogenesis, 
from transcription till binding to the target mRNA, plays a regulatory function that 
controls the production level of miRNAs and regulates the miRNA-mediated gene 
expression regulation. 
!
Figure 1: MicroRNA biogenesis and post-transcriptional gene expression regulation. 
In the nucleus, miRNAs are transcribed by RNA polymerase II/III and producing primary 
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miRNA transcript (pri-miRNA), which is cleaved by Drosha-DGCR8 endonuclease 
complex to produce miRNA precursors (pre-miRNA). The pre-miRNA is exported to the 
cytoplasm through exprotin-5 and then undergoes further processing in the cytoplasm by 
ribonuclease Dicer generating miRNA duplex. The duplex unwinds producing a single 
stranded mature miRNA that is incorporated into RISC complex and serve as a guide for 
mRNA targeting resulting mainly in translation inhibition or mRNA degradation. The 
figure was generated using OmniGraffle 6.4.1. 
1.3.2.b MiRNA gene expression regulation 
MiRNAs, which are small noncoding single stranded RNA of around 20 to 25 
nucleotides in length, regulate the expression of more than 30% of the human protein-
coding genes (Xiaohui et al., 2005). They regulate various biological processes including 
cell proliferation, tissue differentiation and developmental timing. The abnormal 
expression of miRNAs is involved in various types of cancers and can be used in 
diagnostic and prognostic analyses (Thomson et al., 2006). Alterations in miRNA 
expression are associated with abnormal cell development in cancer. MiRNAs may act as 
oncogene or tumor suppressor depending on their target gene. MiRNAs mainly act by 
imperfect base pairing with the target mRNA. It mainly represses gene expression by 
destabilization of the transcript or by translational inhibition (Figure 1). A single miRNA 
targets more than one mRNA and the disruption in the miRNA mediated gene regulation 
affects tissue differentiation and is associated with various diseases, including cancer.  
1.3.3 Circulating miRNAs are emerging cancer biomarkers 
Secretory miRNAs were detected in various body fluids, including plasma, serum, urine, 
breast milk and saliva (Hunter et al., 2008; Kosaka et al., 2010). Unexpectedly, miRNAs 
in body fluids showed to be remarkably stable, even under harsh conditions as in repeated 
freezing and thawing, prolonged storage at room temperature, as well as being resistant to 
RNase activity and resistant to extreme pH levels (Mitchell et al., 2008). This high 
stability mainly accounts to miRNA inclusion in microvesicles, exosomes, lipoproteins, 
RNA-binding protein complexes or apoptotic bodies (El-Hefnawy et al., 2004; Hunter et 
al., 2008) (figure-2). Exosomes are double lipid layer 50-90 nm vesicles that are released 
from the donor cells by fusion of multivascular bodies (MVB) with the plasma membrane 
(Février & Raposo, 2004). Microvesicles (MV) are larger vesicles (0.1-1 µm) released 
through outward shedding of the plasma membrane (Hunter et al., 2008). Also, miRNA 
are included in apoptotic bodies (0.5-2 µm), which are shed from cells during apoptosis 
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(Zernecke et al., 2009). Valadi and colleagues showed that exosomal miRNAs are 
secreted from donor cells to the blood stream and are uptaken by endocytosis to regulate 
gene expression in the recipient cell as a form of cell-cell communication (Valadi et al., 
2007).  
!
Figure 2: Circulating miRNA packaging and release into blood stream. Mature 
miRNAs are released from the cell through various mechanisms, including sorting into 
MVB that are discharged by exosomes, outward shedding of microvesicles that 
encompass miRNA, miRNA may also be released by incorporation into RNA-binding 
proteins or high-density lipoproteins (HDL). Also, apoptotic bodies could convey 
miRNAs into the blood stream. Circulating miRNAs also serve in cell-to-cell 
communication. The figure was generated using OmniGraffle 6.4.1. 
The levels of circulating miRNAs are highly affected by various diseases including 
cancer. Therefore, they are considered as minimally invasive potential biomarkers for the 
diagnosis and prognosis of cancer. Selected cellular miRNAs showed be designated for 
extracellular release via exosomes. Where, Pigati and colleagues reported that only 66% 
of the cellular miRNA are released to the extracellular space at levels corresponding to 
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the cellular miRNA levels (Pigati et al., 2010) and 21% of the cellular miRNAs were 
found at excessively higher levels in the cell-derived exosomes than that of the mother 
cells. The remaining 13% of the miRNAs were selectively kept inside the cell without 
extracellular release. Moreover, the selection of the secreted miRNAs was significantly 
affected by malignancy (Pigati et al., 2010). The selective miRNA release could also 
reflect the stage of cancer, the response to treatment, metastasis and cancer prognosis. 
This infers that the cell employs certain mechanisms to designate certain miRNAs to be 
released via the vesicles to the body fluids. These mechanisms of secretory miRNAs 
selection and the role of these circulatory miRNAs are still not fully understood.  
1.3.4 Circulating miRNAs in ovarian cancer 
Taylor and Gercel-Taylor showed that the levels of circulating tumor-derived exosomes 
were significantly elevated in ovarian cancer patients relative to patients with benign 
ovarian tumor and healthy females. (Taylor & Gercel-Taylor, 2008). Several miRNAs 
were identified to be dysregulated in the serum of ovarian cancer patients. Resnick and 
colleagues identified five miRNAs, miR-21, miR-92, miR-93, miR-126 and miR-29a, 
elevated in the serum of ovarian cancer patients and another three downregulated 
miRNAs, miR-155, miR-127 and miR-99b (Resnick et al., 2009). Serum miR-145 was 
described to be downregulated in ovarian cancer patients compared to healthy controls 
(Table 1) (Liang et al., 2015). In another study, the combination of the elevated plasma 
miR-205 levels and reduced plasma let-7f levels in ovarian cancer patients were proposed 
as a potential diagnostic tool (Table 1) (Kan et al., 2012; Zheng et al., 2013). Serum miR-
200 family were found to be elevated in other cancer types including colorectal cancer 
(Toiyama et al., 2014), gastric cancer (Valladares-Ayerbes et al., 2012), breast cancer 
(Antolin et al., 2015) and hepatocellular carcinoma (Dhayat et al., 2015).  
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Table 1: Summary of the dysregulated extracellular miRNAs in ovarian cancer. 
Differentially expressed miRNAs 
The body 
fluid 
Approach AUC* Sensitivity Specificity Population Reference 
Combination of miR-205 (Up) + 
Let-7f (Down) 
Plasma 
TaqMan low-
density array  
Real-time- PCR 
0.831  62.4% 92.9% 
EOC (n=260), Healthy 
controls (n=200) 
(Zheng et 
al., 2013) 
miR-200c (Up) 
miR-141 (Up) 
Serum Real-time PCR 
0.79 
0.75 
72% 
69% 
70% 
72% 
EOC (n=74), Healthy 
controls (n=50) 
(Gao & 
Wu, 2015) 
miR-21, miR-92, miR-93, miR-
126 and miR-29a (Up) 
miR-155, miR-127 and miR-99b 
(Down) 
Serum 
TaqMan Array 
Human 
MicroRNA panel  
Real-time PCR 
n/a** n/a n/a 
EOC (n=28), Healthy 
controls (n= 15)  
(Resnick et 
al., 2009) 
miR-145 (Down) Serum Real-time PCR 0.82  n/a n/a 
Malignant OVCA 
(n=84), Healthy control 
(n=135) 
(Liang et 
al., 2015) 
miR-106b, miR-126, miR-150, 
miR-17, miR-20a, and miR-92a  
(Up) Plasma 
Taqman Open 
Array MicroRNA 
pools  
<0.8 
>0.8 
n/a n/a 
Serous EOC (n=42), 
Healthy controls (n=23) 
(Shapira et 
al., 2014) 
miR-92 (Up) Serum Real-time PCR 0.8 80.7% 75% 
EOC (n=50), Healthy 
controls (n-50) 
(Guo et al., 
2013) 
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miR-30a-5p (Up) Urine 
miRNA 
microarray 
Real-time PCR 
0.862 n/a n/a 
Serous EOC (n=39), 
Healthy controls (n=30) 
(Zhou, 
2015) 
miR-221 (Up) Serum Real-time PCR n/a n/a n/a 
EOC (n=96), Healthy 
controls (n=35) 
(Hong et 
al., 2013) 
miR-21 (Up) 
 
Serum Real-time PCR n/a n/a n/a 
EOC (n=94), Healthy 
controls (n=40) 
(Yun-Zhao 
Xu1, 2013) 
U2-1 snRNA (Up) Serum 
Microarray  
Real-time PCR 
n/a n/a n/a 
OVCA (n=119), 
Healthy controls (n=35)  
(Kuhlmann 
et al., 
2014) 
*AUC: area under the receiver operating characteristic curve. 
** n/a: not available 
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1.4 Scope of the study and Study objectives 
Various miRNAs were reported to have a role in EOC development. However, the role of 
miR-590-3p in EOC was not studied before. Here, we employed various bioinformatics 
analysis to identify the potential role of miR-590-3p in EOC development. Our initial 
analysis suggested that miR-590-3p could have a role in tumor initiation, through 
regulating vital cellular pathways including cell differentiation processes. Additionally, 
the diagnostic potential of the circulating miR-590-3p was never investigated in cancer 
patients, despite being listed among the twenty most abundant miRNAs in most of the 
body fluids (Weber et al., 2010). Our aim is to study the levels of circulating miR-590-3p 
in the serum as a potential minimally invasive biomarker for the diagnosis of EOC, as 
well as investigating its potential role in EOC carcinogenesis. The human miR-590-3p 
(hsa-miR-590-3p) is an intragenic intronic miRNA, 21 nucleotides in length, located 
within intron number 5 of the eukaryotic initiation factor 4H (EIF4H) gene and is located 
at chromosome 7: 73605528-73605624 [+]. The basic expression of miR-590-3p was 
detected at its highest levels in the heart, followed by the testes and the kidneys; 
nonetheless minimal levels were detected in the brain and the cerebellum.  
Previous studies described the role of miR-590-3p in stem cells. In normal human 
mesenchymal stem cells, miR-590-3p ectopic expression increased cell proliferation and 
clonogenicity, as well as reducing cellular senescence via the direct downregulation of 
aminoacyl- tRNAsynthetase-interacting multifunctional protein-3 (AIMP3/p18), which is 
also a tumor suppressor gene (S. Lee et al., 2014). Also, miR-590 plays a role in DNA 
repair of the double strand breaks and the single strand breaks that could occur during the 
rapid proliferation of the mouse embryonic stem cells (mESCs), without affecting its 
stemness features (Liu et al., 2014). In adult cardiomyctes that have limited low 
proliferation ability, miR-590-3p induced-expression resulted in cell cycle re-entry and 
promoted adult cardiomyocytes proliferation (Eulalio et al., 2012).  
In previous studies, altered expression of miR-590-3p was detected in bladder cancer, 
glioblastoma and hepatocellular carcinoma. Nevertheless, the published studies about 
miR-590-3p in cancer reached opposing or inconsistent conclusions. In bladder cancer, 
miR-590-3p was downregulated relative to the normal and adjacent tumor tissues and 
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induced-overexpression of miR-590-3p in bladder cancer cell lines inhibited cell 
proliferation, migration and colony formation (Mo et al., 2013). On the other hand, miR-
590-3p was significantly upregulated in in hepatocellular carcinoma (HCC) tissues and 
cell lines, and the ectopic expression of miR-590-3p promoted HCC cell proliferation (H. 
Yang et al., 2013). Yan and colleagues examined miRNA expression in 116 samples of 
low-grade gliomas, anaplastic gliomas and secondary glioblastomas using microarray and 
quantitative real-time PCR analysis and they reported that miR-590-3p was significantly 
upregulated in anaplastic gliomas and secondary glioblastomas relative to low-grade 
gliomas, in both the microarray screening cohort and the qPCR validation cohort (Yan et 
al., 2014). However, in a recent study that was also about glioma, Pang and colleagues 
reported that miR-590-3p was downregulated in glioma tissues and cell lines compared to 
non-neoplastic brain tissues and primary normal human astrocytes (Pang et al., 2015). 
The differing data about the expression pattern of miR-590-3p in cancer suggests that 
miR-590-3p could play its role in a certain stage of tumor development, thus further 
studies need to be conducted to clarify the role of miR-590-3p in carcinogenesis. 
The specific objectives of the study are: 
1. Studying the diagnostic ability of the circulating miR-590-3p by examining its 
levels in EOC patients’ serum, as well as the levels of miR-590-3p in EOC tissues 
relative to healthy controls. The experimental design of the real-time PCR 
experiments is illustrated in Figure 3. 
2. Studying the potential association of miR-590-3p levels with epithelial-
mesenchymal transition.  
3. Investigating the potential role of miR-590-3p in EOC through studying its 
potential downstream targets in EOC. 
4. Studying the expression profiles of miR-590-3p in different cancer types, through 
utilizing the expression data available at The Cancer Genome Atlas (TCGA) Data 
Portal. 
! 12!
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Figure 3: Schematic flow chart of the Taq-man quantitative real-time PCR 
experiments. A) Whole blood collection by venipuncture and serum separation, followed 
by RNA extraction and synthetic spike-in control was used as internal control. B) EOC 
tissues were snap frozen in liquid nitrogen directly after being dissected from patients, 
and then, placed in RNAlater-ICE Frozen tissue transition solution, followed by total 
RNA extraction using Triazol reagent. C) MiRNA reverse-transcription using miRNA-
specific stem-loop primers and quantitative real-time PCR using TaqMan MicroRNA 
Assays. Figure generated using OmniGraffle 6.4.1. !
 
 
 
 
 !
 !
 !
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CHAPTER 2 
Materials and Methods 
2.1 Study participants and sampling 
The blood samples were collected from 13 patients with EOC prior to surgery. One blood 
sample from patient with benign ovarian tumor and six blood samples from age-matched 
healthy females with no history of cancer, were obtained as controls. The whole blood 
was collected by venipuncture, and then serum was separated by centrifugation at 10,000 
rpm for 10 min and stored at -80OC (Figure 3). 
Twenty EOC tissue samples were obtained from tumor dissection surgeries at the 
Oncology Center of Mansoura University starting from December 2013 till June 2015.  
International Federation of Gynecology and Obstetrics (FIGO) staging was used for 
clinical staging of the tumor. Imaging scans was obtained before surgery to determine the 
stage of ovarian cancer. The tumor grade was assessed through histo-pathological 
examination. The histo-pathological examination was performed at the oncology Center 
of Mansoura University. The EOC tissues were fixed with fixative solution and 
embedded in paraffin, then sectioned with a microtome. Dewaxed sections were stained 
using hematoxylin and eosin (H&E). Six healthy ovarian tissues from hysterectomy 
surgeries and one benign ovarian tumor were included in the study. The clinical 
characteristics of the patients are summarized in Table 2. The excised tissues were snap 
frozen, in liquid nitrogen, directly after being dissected from the patients. The snap frozen 
tissues were placed in RNAlater-ICE Frozen tissue transition solution and stored at -
800C. The Institutional Review Board (IRB) of the American University in Cairo 
approved the protocols followed in this study. All patients provided informed consents. 
Table 2: Summary of the clinical characteristics of patients in the study. 
Variables OVCA Tissue Profiling 
Group  
(n=20) 
OVCA Serum Profiling 
Group  
(n=13) 
Age    
Mean 51 54 
Minimum 30 44 
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Maximum 65 65 
Histological Type   
Serous 18 13 
Endometrioid 1 0 
Mucinous 1 0 
FIGO Clinical Stage   
1B 6 4 
2B 1 0 
3C 10 7 
 
4 3 2 
Histological Grade   
Well Differentiated       
(Grade-I) 
11 6 
Moderately Differentiated 
(Grade-II) 
5 5 
Poorly Differentiated 
(Grade-III) 
4 2 
2.2 Total RNA extraction from serum and tissue samples 
RNA from the serum samples was extracted using Qiagen miRNeasy Serum/Plasma Kit 
(Qiagen). Frozen serum samples were allowed to thaw completely on ice and were mixed 
gently by inversion.  Serum samples were filtered through 0.22µm filter to remove any 
remaining cellular contents that were not removed by centrifugation.  One part of each 
serum sample was mixed with 5 parts of Qiazol. MiRNeasy Serum/Plasma Spike-In 
Control (1.6 x 108 copies/µl of synthetic C. elegans Cel_miR-39-3P miRNA mimic 5’-
UCACCGGGUGUAAAUCAGCUUG-3’) was used as internal control by adding 3.5 µl 
of the spike-in control prior to the addition of chloroform to normalize the variation in 
RNA extraction and amplification efficiency between samples. The RNA extraction for 
serum was resumed following the manufacturer's instructions.  
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Total RNA was extracted from the frozen tissue samples using Triazol reagent 
(Invitrogen, USA) according to the manufacturer's instructions. In 1.5 ml Rnase-free 
Eppendorf tubes, frozen sections of the tissues were mechanically homogenized in 
Triazol using sterile pestles. Then after addition of chloroform, the aqueous phase was 
transferred into clean tube. Total RNA was precipitated using ice-cold isopropyl alcohol 
and pelleted by centrifugation. The formed pellet was washed, twice, with 75% ethanol. 
Then, the pellet was air-dried, and then re-suspended in DEPC-treated water. 
The RNA concentration was assessed using the Nanodrop RiboGreen assay kit 
(Molecular Probes Cat. # R11490) using NanoDrop-3300 Fluoro-spectrometer (Thermo 
Scientific, USA). The A260/A280 ratio was measured by using spectrophotometer UV-
1800 (Shimadzu, Japan) to assesse the RNA purity.  
2.3 Semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) 
First Strand cDNA was synthesized using random primers from 1 µg RNA by RevertAid 
First Strand cDNA synthesis Kit (Thermo Scientific, USA) according to the 
manufacturer’s instructions. The PCR reaction was carried out by mixing 1 µl cDNA 
template, 2.5 µl 10X DreamTaq PCR buffer, 0.5 µl 10mM dNTPs, 0.25 µl Dream Taq 
Polymerase, 0.75 µl primers (forward and reverse primers) and nuclease-free water for a 
total volume of 25 µl. The expression level of the genes was normalized using GAPDH 
as endogenous control. The thermo-cycler program is 95°C for 5 mins, followed by 
cycles of (95°C for 30 secs, annealing temp for 30 secs and 72°C for 45 secs). The 
annealing temperatures and cycle number is indicated in Table 3. We ran the PCR 
products on a 1.5% agarose gel then visualized using Gel Doc EZ System (Bio-Rad, 
USA).  
Table 3: Primers used for semi-quantitative RT-PCR. 
Primer Sequence Annealing 
temperature 
Number 
of cycles 
GAPDH F*: 5'-
CCACCCATGGCAAATTCCATGGCT-3' 
R**: 5'-
TCTAGACGGCAGGTCAGGTCCACC-3' 
60.5°C 30 
cycles 
MUCIN16/
CA125 
F: 5’-ACATCAACTCCTGCCTTCCCAGAA-
3’  
R: 5’-
57°C 30 
cycles 
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ACCAGTGGGCATTCCAGAAAGAGA-3’ 
CRP F: 5’-
TCGTATGCCACCAAGAGACAAGACA-3’ 
R: 5’-
AACACTTCGCCTTGCACTTCATACT-3’ 
58 °C 38 
cycles 
PAX2 F: 5’-GTACTACGAGACCGGCAGCATC-3’ 
R: 5’-CGTTTCCTCTTCTCACCATTGG-3’ 
58°C 35 
cycles 
Vimentin F: 5’-GAACGCCAGATGCGTGAAATG-3’  
R: 5’-CCAGAGGGAGTGAATCCAGATTA-
3’ 
60 °C 35 
cycles 
E-
Cadherin 
F: 5'-CCTTCCTCCCAATACATCTCCC-3' 
R: 5'-TCTCCGCCTCCTTCTTCATC-3' 
58°C 33 
cycles 
LEF1 F: 5'-ACAGCGGAGCGGAGATTACAGAG-
3' 
R: 5'-TCCCTTGTTGTAGAGGCCTCCATC-
3' 
60°C 35 
cycles 
SOX2 F: 5'-TTACCTCTTCCTCCCACTCC-3' 
R: 5'-CCTCCCATTTCCCTCGTTT-3' 
57°C 37 
cycles 
*Forward primer, **Reverse primer. 
2.4 Quantitative real-time RT-PCR 
MicroRNA-590-3p levels in the serum and tissues were analyzed using Taq-Man 
MicroRNA Assays (Applied Biosystems, USA). Ten ng of the total RNA was reverse-
transcribed using miRNA-specific stem-loop primers and Taq-Man miRNA Reverse 
Transcription Kit in a scaled down 5µl reaction. The RT reactions were incubated for 30 
min at 16 °C, then for 30 min at 42 °C, and then for 5 min at 85 °C. The RT products 
were stored at -20 °C till running the real-time PCR reaction. The real-time PCR reaction 
was performed using Taq-Man MicroRNA Assays (Table 4) (Reporter dye: FAM and 
reporter quencher: NFQ) on Mx3005P QPCR System (Stratagene). The cDNA was 
mixed with the PCR primers and probes (5'-FAM and 3'-TAMRA), and Taq-Man 
Universal Master Mix, No AmpEraseH UNG (Applied Biosystems), then incubated at 95 
°C for 10 min, followed by 40 cycles of 95°C for 15 sec and 60°C for 1 min. Automatic 
setting for assigning the baseline and threshold for Ct determination was used. A Ct of 35 
was set as cut-off value to be considered as non-detected (Caraguel et al., 2011). For the 
serum samples, Synthetic C. elegans Cel_miR-39 miRNA mimic was used as internal 
control (validated control by (Zhang et al., 2013). The expression level of the tissue miR-
590-3p was normalized to U6 snRNA. Each measurement was performed in duplicates 
including the no-template controls and the no-reverse transcriptase controls. The relative 
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quantification of miR-590-3p was estimated using the comparative ΔΔCT method (Livak 
& Schmittgen, 2001).  
Table 4: Taq-Man MicroRNA Assays 
MicroRNA 
Accession 
Number 
MicroRNA Assay 
Name 
Assay 
ID 
MicroRNA sequence 
MIMAT000
4801 
Hsa-miR-590-3p 002677 UAAUUUUAUGUAUAAGCUAGU 
NR_004394 U6 snRNA 001973 GTGCTCGCTTCGGCAGCACATAT
ACTAAAATTGGAACGATACAGAG
AAGATTAGCATGGCCCCTGCGCA
AGGATGACACGCAAATTCGTGAA
GCGTTCCATATTTT 
MIMAT000
0010 
Cel-miR-39 000200  UCACCGGGUGUAAAUCAGCUUG 
2.5 Western blot analysis 
Protein lysates were prepared by mechanical homogenization of the tissues in 2X ice-cold 
Laemmle lysis buffer (50mM Tris pH6.8, 2% sodium dodecyl sulfate (SDS), and 10% 
glycerol) with freshly added 1X Halt Protease Inhibitor Cocktail (ThermoScientific, 
USA). Then, the samples were incubated at 4°C for 2 hours, followed by centrifugation at 
12,000 rpm at 4°C for 20 minutes. The supernatant protein lysates were transferred into 
fresh Eppendorf tubes and quantified using Pierce BCA Protein Assay Kit (Pierce 
Biotechnology, USA) according to the manufacturer's instructions. Serial dilution of the 
standard bovine serum albumin (BSA) of known concentration was prepared to generate 
the standard curve. Optical density was taken at 562nm using spectrophotometer and the 
working reagent was used as a blank. 
Equal concentrations of the protein lysates (30µg) were mixed with 6X SDS-Laemmli 
loading dye (60% Glycerol, 360 mM Tris-HCl pH 6.8, 12% SDS, 0.06% bromophenol 
blue, 30% beta-mercaptoethanol) and boiled at 99°C for 5 minutes. The samples were 
loaded on 12% SDS- polyacrylamide gel, and then plotted on a PVDF membrane. After 
blocking the membrane with 5% nonfat dry milk in PBS with 0.01% Tween 20 for 1 
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hour, the membrane was incubated with anti-SOX-2 rabbit polyclonal antibody 
(0.5µg/ml), or anti-LEF1 goat polyclonal antibody (2µg/ml) overnight at 4°C. After 
washing, we incubated the membrane in goat anti-rabbit or mouse anti-goat alkaline 
phosphatase-conjugated secondary antibody  (KPL) (1:10000 dilution in 5% non-fat dry 
milk in PBS-T). After washing, the protein bands were detected using Phosphatase 
Chemiluminescent Substrate. 
To examine the loading control on the same membranes, the membranes were incubated 
with harsh stripping buffer (0.5 M Tris-HCl, 10% SDS and beta-mercaptoethanol) for 15 
minutes at 65°C, then washed thoroughly with water to remove any traces of beta-
mercaptoethanol. The membranes were blocked with blocking solution for one hour, then 
incubated with anti-β-Tubulin mouse monoclonal antibody (Sigma, T7816) (1:20,000 in 
5% non-fat dry milk) overnight at 4°C. After washing, we incubated the membrane in 
goat anti-mouse alkaline phosphatase-conjugated secondary antibody (KPL) (1:10000 in 
5% non-fat dry milk in PBS-T). After washing, the protein bands were detected using 
Phosphatase Chemiluminescent Substrate. 
2.6 Target gene prediction and miRNA function prediction analysis 
MiR-590-3p potential target genes were predicted using TargetScan (Agarwal et al., 
2015) (www.targetscan.org), and miRanda-mirSVR (Betel et al., 2010; Betel et al., 2008; 
John et al., 2004) (www.microrna.org). The thermodynamic stability between miR-590-
3p and the 3’UTR of LEF1 mRNA and PAX2 mRNA was predicted using miRmap 
(http://mirmap.ezlab.org/ app/). The expression profiles of the potential target genes were 
examined using Oncomine data-mining platform (http://www.oncomine.org) (Rhodes et 
al., 2004) that covers cancer microarrays. StarBase Pan-cancer analysis platform 
(http://starbase.sysu. edu.cn/pan Cancer.php) (Li et al., 2014; J.-H. Yang et al., 2011) was 
used to compile the expression profiles of miR-590-3p and LEF1 utilizing the data 
available at The Cancer Genome Atlas (TCGA) Data Portal and to study the correlation 
between their expression levels in ovarian cancer. 
We used FAME (Functional Assignment of MicroRNAs via Enrichment) software 
(Ulitsky et al., 2010) (http://acgt.cs.tau.ac.il/fame/) to predict the potential function of 
miR-590-3p through analyzing its downstream target genes. 
! 19!
2.7 Statistical analysis 
The relative expression of miR-590-3p was calculated using the comparative ΔΔCT 
method (Livak & Schmittgen, 2001). The relative levels of miR-590-3p were presented 
as log transformed log10 (2-ΔΔCT) of the relative levels of miR-590-3p. Serum miR-590-
3p levels were used to generate the receiver operating characteristic (ROC) area under the 
curves (AUC) to study the ability of miR-590-3p to distinguish between the EOC patients 
and healthy females. Linear regression analysis was used to analyze the correlation 
between miR-590-3p levels and the levels of the potential down-stream target genes. 
ImageJ software (http://www.imagej.nih.gov/ij) was used for densitometric analysis to 
analyze the results of the semi-quantitative PCR and the western blot and for 
normalization to the endogenous control. Data are presented as mean ± standard 
Deviation (SD). For statistical comparisons, the The Mann–Whitney test was carried out.  
A probability value (P-value) <0.05 was considered to indicate statistical significance. 
One-way ANOVA (with Bonferroni post-test) was carried out to analyze the difference 
between multiple experimental groups with a single variable. Statistical analyses were 
performed using GraphPad Prism 6 statistical packages.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 !
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CHAPTER 3 
Results 
3.1 Clinico-pathologic Characteristics 
The blood samples were collected from 13 patients prior to surgery, four patients at early 
stage (stage I/II) and nine patients at advanced stage (stage III/IV) (Table 2). Six blood 
samples were collected from healthy females with no history of cancer and one obtained 
from a patient with benign ovarian tumor. The EOC tissue samples were collected from 
20 patients. The clinical characteristics of the patients are summarized in Table 2 and 5. 
The clinical stage distribution among the enrolled patients for tissue sampling is six 
patients (30%) at stage-I, one patient (5%) at stage-II, ten patients (50%) at stage-III and 
three patients (15%) at stage-IV.  We examined the histological grade of the EOC tissues. 
Eleven samples (55%) were characterized as well differentiated grade-I, five (25%) as 
moderately differentiated grade-II and four (20%) EOC samples as poorly differentiated 
grade-III (Figure 4). Different histological subtypes of EOC were involved including 
serous EOC, which represents 18 cases, and also endometrioid and mucinous EOC were 
included. The mean age of EOC patients is 51 (age range 30-65) years. The control 
ovarian tissues were collected from 6 healthy controls with no history of cancer from 
hysterectomy surgeries, and one patient with benign ovarian tumor, with mean age of 55 
years (age range 50-63).  
Table 5: Clinical characteristics of EOC patients in the study. 
Sample 
ID FIGO Stage 
Histological 
Grade 
CA 125 
(U/ml) 
Pre-operative 
chemotherapeutic 
treatment 
Metastasis at 
diagnosis 
C1 III C Grade-I 430 Treated Metastasis to lymph 
C2 IIB Grade-III 220 Treated N
o M
etastasis 
 
C3 III C Grade-I >600 Not Treated 
C4 IB Grade-I 470 Not Treated 
C5 III C Grade-I 116 Not Treated 
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C6 IB Grade-III >600 Treated No M
etastasis 
C7 1B Grade-I 6.15 Not Treated 
C8 IV Grade-III 7 Not Treated 
C9 IB Grade-I 10 Not Treated No Metastasis 
C10 IV Grade-III 533 Treated Metastasis to lymph 
C11 IIIC Grade-II 97 Treated 
N
o 
M
etastasis 
C12 IB Grade-I 79 Treated 
C13 IB Grade-I 48 Not Treated 
C14 IIIC Grade-II >600 Treated Metastasis 
C15 IV Grade-II >600 Not Treated 
N
o M
etastasis 
 
C16 IIIC Grade-I 90 Not Treated 
C17 IIIC Grade-II 70 Not Treated 
C18 IIIC Grade-II 110 Not Treated 
C19 IIIC Grade-I >600 Not Treated 
C20 IIIC Grade-I >600 Not Treated 
CS*-1 IIIC Grade-III >600 Treated Metastasis 
CS-2 IB Grade-I >600 Not Treated No Metastasis *!Cancer!serum!(Serum!specimens!only)!!!!!!!!!!
Table 6: The levels of tissue CRP in different stages of EOC 
FIGO Stage! Tissue CRP mRNA Levels! EOC$Samples$
IB$ Absent!! A!Low! C6,!C7,!C9,!C4!High! C12,!C13!
IIB$ Absent!! A!Low! C2!High! A!
IIIC$ Absent!! C20!Low! C5,!C14,!C16,!C19!High! C1,!C3,!C11,!C17,!C18,!
! 22!
IV$ Absent!! A!Low! C8!High! C10,!C15!!
Table 7: The levels of tissue PAX2 in different histological grades. 
Histological Grade$ Tissue PAX2 mRNA Levels$ EOC$Samples$
Grade2I$ Absent!! C3,!C7,!C9,!C12,!C13,!C16,!C20!Low! C4,!C19!High! C1,!C5!
Grade2II$ Absent!! C11,!C14,!C15,!C17,!C18!Low! A!High! A!
Grade2III$ Absent!! C2,!C6,!C8,!C10!Low! A!High! ! A!!
!
Figure 4: Histological grade of EOC samples. The figure shows representative samples 
from each histological grade A) A well-differentiated grade-I sample with uniform, 
small, and round to oval nuclei. B) The grade-II sample was characterized by uniform 
nuclei that are larger than that of the low-grade but smaller than the high-grade nuclei. C) 
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The high-grade nuclei are larger with greater pleomorphism and increased nuclear-to-
cytoplasmic ratio. The insets at higher magnification highlight the nuclear features at 
different grades (indicated by an arrow). (Hematoxylin and Eosin stains). 
3.2 Histo-pathological characterization at the molecular level 
Intra-tumoral heterogeneity of cellular phenotypes is a challenging factor in the 
assessment of the histo-pathological characters of the tumor and correlating the levels of 
biomarkers to the tumor features.  The heterogeneity of cellular phenotype within the 
tumor mainly stems from the gradient level of differentiation within neoplasms, the 
different levels of interactions between tumor cells via intercellular vesicles (exosomes), 
and the effect of the microenvironment on the tumor cells (Fidler & Hart, 1982). To 
perform a reliable correlation between miR-590-3p levels and the tumor characteristics, 
we analyzed the histo-pathological features at the molecular level via examining the 
mRNA steady-state levels of molecular biomarkers using RT-PCR. So that, the same 
aliquot is being examined for the levels of biomarkers related to the histo-pathological 
status of the tumor, as well as the levels of miR-590-3p. We examined the expression of 
various acknowledged biomarkers including CA125/Mucin16 which is being used for 
EOC screening (Høgdall et al., 2007) and C-reactive protein (CRP) which expression was 
correlated with the stage of the disease, as higher expression of CRP was associated with 
late stages of EOC (Hefler-Frischmuth et al., 2009). And, paired homeobox 2 (PAX2) 
gene expression, which was found to show different expression levels in low-grade 
versus high grade EOC, was used as a marker for the EOC grade (Tung et al., 2009). 
The average CA125/Mucin16 blood level of the cases in the study is ≈ 290 U/ml (n=20). 
85% of patients exhibited high CA125/Mucin16 blood levels (above the normal threshold 
35U/ml), whereas the other 15% of patients (C7, C8 & C9) had normal levels of blood 
CA125/Mucin16, despite being diagnosed with OVCA (Table 5). At the level of tissue 
expression, the tissue mRNA steady-state levels of CA125/Mucin16 were elevated in 
about 70% of the EOC tissue samples. Its levels were low in six EOC samples including 
four samples from patients subjected to platinum-based combination chemotherapy (C1, 
C2, C6, C10) (Figure 5). As expected the tissue mRNA steady-state level of CRP were 
associated with the clinical stages of EOC. Higher levels of CRP were observed at 
advanced stages of EOC, relative to the early-stage EOC, except for two early-stage EOC 
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samples (C12&C13) that showed high levels of CRP (Table 6) (Figure 6). In agreement 
with what has been reported in the literature (Tung et al., 2009), high PAX2 tissue 
mRNA levels were observed in the majority of low-grade EOC (C1, C4, C5 and C19) 
and PAX2 expression was completely diminished in high-grade EOC (C2, C6, C8, C10, 
C11, C14, C15, C17, and C18) (Table 7) (Figure 7). The abolished PAX2 expression in 
the ovarian mucinous carcinoma (C7) is in accord with previous studies that detected 
PAX2 expression in ovarian serous and endometrioid carcinoma, but not in the ovarian 
mucinous carcinoma (Schaner et al., 2003; Wang et al., 2015). 
 
!
Figure 5: RT-PCR analysis of tissue CA125/Mucin16 shows elevated levels in EOC 
relative to control tissues (P=0.0001). The intensities of the semi-quantitative PCR 
bands were normalized to the endogenous control GAPDH using ImageJ. N1 –N6 
represent healthy ovarian tissues, B1 is benign tumor and C1-C20 represent EOC 
samples. (***P<0.0005) 
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Figure 6: Higher levels of CRP were associated with advanced stages of EOC. The 
early-stage EOC samples are C2, C4, C6, C7, C9, C12, and C13. However, C1, C3, C5, 
C8, C10, C11, C14, C15, C16, C17, C18, C19 and C20 are late-stage EOC. The 
intensities of the semi-quantitative PCR bands were normalized to the endogenous 
control GAPDH using ImageJ. N1 –N6 represent healthy ovarian tissues, B1 is benign 
tumor and C1-C20 represent EOC samples. 
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Figure 7: The level of PAX2 mRNA in EOC samples is a marker for EOC 
histological grade. The histological low-grade EOC samples are C1, C3, C4, C5, C7, C9, 
C12, C13, C16, C19 and C20. The histological higher-grade (grade-II/III) samples are 
C2, C6, C8, C10, C11, C14, C15, C17, and C18. PAX2 expression was completely 
diminished in high-grade EOC. 
3.3 Upregulation of serum miR-590-3p in EOC patients 
We examined the expression levels of miR-590-3p in the serum of 13 EOC patients, and 
7 controls using qRT-PCR.  The levels of miR-590-3p in the serum of EOC patients 
(84.6%) were significantly higher than that of the healthy controls (P=0.04) (Figure 8). 
Interestingly, the levels of miR-590-3p in C9 that showed normal level of pre-operative 
blood CA125/Mucin16 (below 35U/ml) was significantly elevated compared to healthy 
controls. We analyzed the correlation between miR-590-3p serum levels and the clinico-
pathological features of EOC. The patients were categorized into two groups according to 
the stage, the early-stage group (stage I/II, n=4) and late-stage group (stage III/IV, n=9), 
and two groups according to the tumor differentiation grade, group of histological grade-I 
(n=6) and group of histological grade-II/III (n=7). We found that there was no significant 
difference in the serum miR-590-3p levels between the different stages (Figure 9A). 
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Likewise, no significant difference was observed among the patients with different tumor 
differentiation grade (Figure 9B). Also, receiving pre-operative chemotherapeutic 
treatment didn’t affect serum miR-590-3p levels (Figure 9C). Additionally, there was no 
significant correlation between serum miR-590-3p and metastasis (Figure 9D). It is worth 
noting that we were limited to the small sample size of metastasis cases (n=3).  
!
Figure 8: miR-590-3p is significantly elevated in EOC patients' serum. Box plot 
represents serum miR-590-3p expression levels in controls and EOC patients. The level 
of serum miR-590-3p was normalized to the synthetic C. elegans Cel_miR-39 Spike-in 
control. The upper and lower borders of the boxes indicate the 75th and 25th percentiles, 
respectively. The whisker caps indicate the 90th and 10th percentiles. The horizontal 
lines in the boxes indicate the median values. P-value was depicted using the Mann–
Whitney U-test. The relative levels of miR-590-3p are presented as log transformed 
log10 (2-ΔΔCT) of the relative levels of miR-590-3p. (* P<0.05) 
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Figure 9: The correlation between serum miR-590-3p levels and EOC clinico-
pathological features. (A) Serum miR-590-3p did not significantly differ among EOC 
patients with different clinical stages, (B) or in EOC patients with different histological 
grades. (C) Serum miR-590-3p levels were not affected by pre-operative 
chemotherapeutic treatment, (D) and showed no significant correlation with the existence 
of metastasis. The upper and lower borders of the boxes indicate the 75th and 25th 
percentiles, respectively. The whisker caps indicate the 90th and 10th percentiles. The 
horizontal lines in the boxes indicate the median values. One-way ANOVA (with 
Bonferroni post-test) was carried out to analyze the statistical significance. (P>0.05) 
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3.4 Serum miR-590-3p level is a promising diagnostic marker for epithelial ovarian 
cancer 
We performed the Receiver–operator characteristic (ROC) curve analysis to study the 
specificity and sensitivity of circulating miR-590-3p to assess its ability to distinguish 
between EOC patients and healthy females. When comparing between serum miR-590-
3p levels in EOC patients and healthy controls, the area under the ROC curve (AUC) was 
0.76 with 95% confidence interval (CI) of 0.54–0.97 and P-value= 0.05 (Figure 10). 
Serum miR-590-3p optimal cut-off value of 2.4 for the 2-ΔΔCT had 76.92% sensitivity and 
71.4% specificity (95%CI=46.19% to 94.96%). We examined the diagnostic ability of 
serum miR-590-3p for stage-I ovarian cancer patients (n=4) versus healthy controls (n=7) 
and the best cutoff value at 4.4 of the 2-ΔΔCT showed 75% sensitivity and 85.71% 
specificity (95%CI=42.13% to 99.64%). The best cutoff value for stage-III/IV patients 
(n=9) versus healthy controls (n=7) was 2-ΔΔCT of 2.4 with 77.78% sensitivity and 71.43% 
specificity (95%CI=40% to 97.1%). On the other hand, as expected from the above 
results, circulating miR-590-3p could not be used to distinguish between EOC patients 
with different clinical stage or tumor differentiation grade. Therefore, our results suggest 
that circulating miR-590-3p is a promising biomarker for diagnosis of early-stage EOC. 
!
Figure 10: Receiver-operator characteristics (ROC) curve analyses of circulating 
miR-590-3p for EOC patients versus healthy controls. Circulating miR-590-3p 
yielded AUC of 76% (P-value= 0.05) with 76.92% sensitivity and 71.4% specificity at its 
optimal cutoff value. 
0 50 100
0
50
100
100% - Specificity%
Se
ns
iti
vi
ty
%
miR-590-3p 
(AUC= 
0.76)
! 30!
3.5 Upregulation of miR-590-3p in EOC tissues 
To study whether the level of serum miR-590-3p corresponds to its expression in EOC 
tissues, we examined the levels of miR-590-3p in 20 EOC tissues, as well as six healthy 
ovarian tissues and one benign ovarian tumor using qRT-PCR. And the level of miR-590-
3p was normalized to U6 snRNA. The expression levels of miR-590-3p were 
significantly elevated in 75% of EOC tissues compared to the benign tumor and the 
healthy ovarian tissues (P<0.05, Figure 11A). Among the 20 EOC samples, 15 samples 
showed elevated miR-590-3p. The level of miR-590-3p was significantly elevated in 
high-grade poorly differentiated EOC (grade II/III) (Figure 11B). Whereas four out of the 
five EOC with low miR-590-3p levels are low-grade well-differentiated EOC. There was 
no significant correlation between tissue miR-590-3p levels and stage, preoperative 
chemotherapeutic treatment or existence of metastasis (Figure 11 C, D & E). We did not 
study the correlation of miR-590-3p levels with progression-free interval or survival due 
to the recent diagnosis of the disease among the enrolled participants.  
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Figure 11: MiR-590-3p expression in EOC tissues. A) MiR-590-3p is significantly 
elevated in EOC tissues compared to controls. B) Significant correlation of tissue miR-
590-3p with high grade EOC. The tissue levels of miR-590-3p didn’t significantly differ 
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among C) different stage, D) existence of metastasis or E) pre-operative 
chemotherapeutic treatment. The relative levels of miR-590-3p are presented as log 
transformed log10 (2-ΔΔCT). The upper and lower borders of the boxes indicate the 75th 
and 25th percentiles, respectively. The whisker caps indicate the 90th and 10th 
percentiles. The horizontal lines in the boxes indicate the median values. (*P<0.05, 
**P<0.005) 
3.6 The correlation between miR-590-3p levels and epithelial–mesenchymal 
transition (EMT) in EOC 
We were limited by the small size of metastatic samples (n=3), to effectively study the 
correlation between miR-590-3p and metastasis. Nonetheless, the above finding (Figure 
11B) that reveals the correlation between tissue miR-590-3p and poorly differentiated 
EOC triggered us to further study the role of miR-590-3p in EOC tumorigenesis. We 
studied the correlation between miR-590-3p levels and EMT in EOC by examining the 
mRNA steady-state levels of EMT- related markers (the epithelial marker E-cadherin and 
the mesenchymal marker Vimentin) in EOC and control tissues. We divided the EOC 
tissue samples into two groups, a high miR-590-3p group and low miR-590-3p group. 
The group with high miR-590-3p indicates miR-590-3p levels more than two folds of that 
of the control and the remaining samples were categorized in the low-miR-590-3p group. 
We observed a correlation between the expression of miR-590-3p and the molecular 
changes of EMT in EOC (Figure 12). As, elevated levels of the mesenchymal marker 
Vimentin was observed in the EOC samples with high miR-590-3p levels indicating that 
miR-590-3p could have a role in EMT in EOC. 
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Figure 12: The mRNA steady state levels of EMT markers in EOC and control 
ovarian tissues. The epithelial marker E-cadherin and the mesenchyme marker Vimentin 
mRNA levels were examined using RT-PCR. The band intestines were normalized to the 
endogenous control GAPDH using ImageJ. The level of the mesenchymal marker 
Vimentin is elevated in the high miR-590-3p expressing EOC samples relative to the 
low-miR-590-3p group (C1, C3, C5, C14 and C20). 
3.7 Bioinformatics analysis of miR-590-3p potential target genes 
MicroRNAs acquire their function via post-transcriptional regulation of their target 
genes. Therefore, to gain an insight to the function of miR-590-3p, we analyzed the 
function of its downsteam targets. We performed functional prediction analysis of miR-
590-3p using FAME software (Ulitsky et al., 2010) and it showed that its target genes 
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were significantly enriched in different biological pathways including oligodendrocyte 
differentiation (P=0.0002), RNA splicing (P=0.0007), glial cell differentiation (0.01), 
metanephros development (0.02) and spermatid differentiation (P=0.03). This indicates 
that the upregulation of miR-590-3p in EOC plays a role in carcinogenesis through 
disrupting key biological processes.  
To study the effect of miR-590-3p upregulation on its downstream target genes in EOC, 
we performed bioinformatics analysis to predict the potential target genes of miR-590-3p, 
utilizing TargetScan (Agarwal et al., 2015), and miRanda-mirSVR (Betel et al., 2010; 
Betel et al., 2008; John et al., 2004) target prediction tools. In miRanda-mirSVR target 
prediction tool, miRanda depicts the potential target genes based on the complementation 
between the seed sequence of the miRNA and its target mRNA and mirSVR score the 
alignment based on the miRNA-mRNA duplex base paring, the A/U content around the 
seed sequence, the mRNA accessibility and the conservation. Also, TargetScan 
demonstrates the conservation of the target sequence, as well as the sequence features, 
including the A/U content, seed region pairing and the location of the target site within 
the 3’UTR of the target gene.   
SOX2 was identified to be a potential target gene by miRanda-mirSVR with a single 
target site for miR-590-3p (Table 8). LEF1 and PAX2 were predicted as downstream 
targets by both TargetScan (Agarwal et al., 2015), and miRanda (Betel et al., 2010; Betel 
et al., 2008; John et al., 2004) (Table 8). Where, LEF1 3’UTR has two potential binding 
sites and PAX2 3’UTR encompasses three potential binding sites for miR-590-3p.  The 
binding sites with the highest miRNA-mRNA thermodynamic stability are presented in 
Table 8. LEF1 target region is conservative among three species of mammals (Homo 
sapiens, Macaca mulatta, Bos Taurus) (Figure 14) and the target region within PAX2 
3’UTR is conserved among various species of mammals (Figure 15A). The 
thermodynamic stability between miR-590-3p and the 3’UTR of LEF1 mRNA or PAX2 
mRNA was calculated using miRmap, which predicted the minimum free energy of the 
miRNA:mRNA duplex (Table 8), and the accessibility of the target region to the miRNA-
RISC complex (Table 8).  
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We, then, filtered the potential target genes through assessing their expression profiles 
using Oncomine data-mining platform (http://www.oncomine.org) (Rhodes et al., 2004) 
and StarBase Pan-cancer analysis platform (http://starbase.sysu. edu.cn/pan Cancer.php) 
(Li et al., 2014; J.-H. Yang et al., 2011). The correlation between the expression profiles 
of miR-590-3p and LEF-1 retrieved from the data available at the cancer genome atlas 
(TCGA) Data Portal using StarBase Pan-cancer analysis platform (Li et al., 2014; J.-H. 
Yang et al., 2011) showed significant negative correlation between their expression levels 
in ovarian cancer. Moreover, the microarray dataset from Bonome study (Bonome et al., 
2008), obtained from  Oncomine data-mining platform, showed significant 
downregulation of  LEF1 in ovarian cancer relative to normal ovarian tissues (Figure 
14C). Similarly, The datasets obtained from the cancer genome atlas (TCGA) ovarian 
cancer gene expression data showed significant downregulation of PAX2 in ovarian 
cancer compared to normal ovaries (Figure 15B), suggesting a negatively correlation 
between miR-590-3p and PAX2 expression in ovarian cancer.  
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Figure 13: Downregulation of SOX2 in ovarian cancer relative to normal ovarian 
tissues. The datasets were retrieved from the cancer genome atlas (TCGA) Data Portal 
using Oncomine cancer database. The upper and lower borders of the boxes indicate the 
75th and 25th percentiles, respectively. The whisker caps indicate the 90th and 10th 
percentiles. The horizontal lines in the boxes indicate the median values and the dots 
represent the minimum and maximum values. 
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Figure 14: Computational analysis depicts LEF1 as a potential target gene for miR-
590-3p. A) LEF1 binding region is conservative among three species of mammals (Homo 
sapiens, Macaca mulatta, and Bos Taurus). B) LEF1 expression is negatively correlated 
with miR-590-3p expression in 268 ovarian cancer samples. The expression data obtained 
from cancer genome atlas (TCGA) data portal using StarBase Pan-cancer analysis 
platform. C) Also, microarray data from Bonome study dataset (Bonome et al., 2008), 
obtained using Oncomine database platform, showed significant downregulation of LEF1 
in ovarian cancer (n=185) compared to normal ovarian tissues (n=10). 
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Figure 15: In silco analysis of PAX2 as a potential downstream target of miR-590-
3p. A) MiR-590-3p binding region within PAX2 3’UTR is conservative among different 
species of mammals, including homosapiens (hsa), pan troglodytes (Ptr), macaca mulatta 
(mml), otolemur garnetti (oga), mus musculus (mmu), rattus norvegicus (rno), cavia 
porcellus (cpo), canis familiaris (cfa), felis catus (fca), bos Taurus (bta), dasypus 
novemcinctus (dno) and monodelphis domestica (mdo), obtained via TargetScan 
(Agarwal et al., 2015). B) Significant downregulation of PAX2 in ovarian cancer (n=586) 
compared to normal ovarian tissues (n=8).  The expression data was obtained from cancer 
genome atlas (TCGA) data portal through Oncomine database platform. !
! 39!
 
Table 8: The alignment features of the putative miR-590-3p targets. 
Predicted 
Target 
genes 
Alignment ΔG* 
duplex 
Access
ibility
** 
A/U 
content
*** 
miRanda-
mirSVR 
Score§ 
Prediction 
algorism 
SOX2 
 
n/a n/a n/a -0.3 miRanda 
LEF1 
 
-1.9 6.46 0.78 -0.83 miRanda, Target 
scan, miR map 
PAX2 
 
-3.6 7.19 0.85 -0.81 miRanda, Target 
scan, miR map 
* Minimum Free Energy (MFE) of miRNA:mRNA duplex (should be minimal for optimal thermodynamic stability). 
** Accessibility of the target site (energy required to unfold the mRNA 3’-UTR). 
***A/U content around the seed (AU-rich 3’UTR is potentially less stable and more accessible). 
§ mirSVR downregulation scores (good score ≤ -0.1). 
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3.8 The expression of the predicted target genes and its correlation with miR-590-3p in 
EOC tissues 
To validate the targets of miR-590-3p, we examined the expression of the potential target genes 
in EOC tissues and analyzed the correlation between their levels and miR-590-3p levels. We 
categorized the EOC samples into two groups, the high miR-590-3p group that includes samples 
with elevated miR-590-3p more than two folds of that of the control and the low miR-590-3p 
group that encompasses the remaining samples. We examined the levels of SOX2 at the mRNA 
and protein levels in representative samples from each group (Figure 16 A & B). Our results 
from examining six EOC samples at the RNA level and 14 EOC samples at the protein level 
showed no significant difference in SOX2 levels between the two EOC groups (Figure 16C). 
Likewise, our results from examining LEF1 mRNA levels in six representative EOC samples and 
LEF1 protein levels in the 20 EOC samples appear to be not agreeing with our in silco results. 
Where the mRNA and the protein levels of LEF1 were not significantly correlated with miR-
590-3p (Figure 16 D, E &F). 
PAX2 mRNA steady state levels were examined (Figure 7). And the levels of PAX2 in EOC 
samples with elevated miR-590-3p were completely diminished. PAX2 mRNA was only detected 
in EOC tissues with relatively lower miR-590-3p levels (Figure 18A). Negative correlation 
between PAX2 and miR-590-3p levels was observed (Figure 18B). Nonetheless, further studies 
need to be conducted to validate PAX2 as a regulatory target of miR-590-3p in EOC and to study 
the direct binding of miR-590-3p to PAX2 3’UTR. 
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Figure 16: SOX2 expression is not significantly correlated with miR-590-3p levels in EOC 
tissues. SOX2 levels in EOC and control ovarian tissues were examined (A) at the RNA level 
using semi quantitative RT-PCR and (B) at the protein level using western blot. The loading 
control β-tubulin was not comparable in the examined samples. Therefore, bands intensities were 
analyzed using ImageJ and normalized to the loading control. C) The normalized SOX2 protein 
levels did not significantly differ in EOC tumors with low levels of miR-590-3p (C1, C3, C5 & 
C20) and high miR-590-3p expressing EOC (C2, C4, C6, C7, C8, C9, C10, C12, C13, & C18). 
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Figure 17: The correlation between LEF1 expression and miR-590-3p in EOC. A) LEF1 
mRNA levels was assessed and B) its normalized levels did not significantly differ in EOC 
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tissues with lower miR-590-3p (C1, C3 &C5) or higher miR-590-3p levels (C2, C4 & C6). C) 
Also, no significant correlation was observed between LEF1 mRNA and miR-590-3p levels. D) 
LEF1 protein levels were examined in EOC and control tissues. E) There was no significant 
correlation between the normalized LEF1 protein and miR-590-3p and F) there was no 
significant difference between LEF1 protein levels in EOC with high miR-590-3p levels and the 
EOC with relatively lower miR-590-3p levels (C1, C3, C5, C14 & C20) 
 
 !
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Figure 18: The correlation between the expression of PAX2 and miR-590-3p. A) PAX2 
expression was associated with EOC samples with lower levels of miR-590-3p (C1, C3, C5, C14 
and C20). B) Negative correlation between the normalized PAX2 mRNA levels and miR-590-3p 
levels was observed. (**P<0.005) 
3.9 MiR-590-3p expression profiles in different cancer types 
Owing to the implied role of miR-590-3p in carcinogenesis, it was worth examining its 
expression pattern in other cancer types. Therefore, we utilized StarBase Pan-cancer analysis 
platform (http://starbase.sysu. edu.cn/pan Cancer.php) (Li, Liu, Zhou, Qu, & Yang, 2014; Yang 
et al., 2011), which encompasses the expression profiles of miRNAs in 14 different cancer types 
that is available at The Cancer Genome Atlas (TCGA) Data Portal, to gain insight to the 
expression of miR-590-3p in various types of cancer. Interestingly, miR-590-3p showed 
inconsistent expression profiles among different cancer types. Nonetheless, there were no data 
fetched from StarBase Pan-cancer analysis platform about miR-590-3p in ovarian cancer. MiR-
590-3p expression was significantly downregulated in papillary thyroid carcinoma with fold 
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change of 0.8 (P=0.002) (Figure 19). However, its levels showed to be upregulated in head and 
neck squamous call carcinoma with fold change of 1.1 (P=0.02) (Figure 19).   
!
Figure 19: Expression profiles of miR-590-3p among different cancer types. MiR-590-3p 
showed different expression profiles among the 14 different cancer types analyzed using 
StarBase Pan-cancer analysis platform. For instance, A) miR-590-3p expression is significantly 
downregulated in papillary thyroid carcinoma samples (P=0.002). However, B) the levels of 
miR-590-3p is upregulated in head and neck squamous call carcinoma (P=0.02).  Data source is 
StarBase Pan-cancer analysis platform (http://starbase.sysu. edu.cn/pan Cancer.php) (Li, Liu, 
Zhou, Qu, & Yang, 2014; Yang et al., 2011). 
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CHAPTER 4 
Discussion, Conclusions and Future directions 
EOC accounts for 90% of the ovarian malignancies, which is the most lethal gynecological 
cancer (Howlader N, 2015). The high mortality rate in ovarian cancer mainly stems from the late 
diagnosis at advanced stages. As, the five-year survival rate in the patients diagnosed at an 
advanced stage is only 21%; whereas the five-year survival rate is more than 90% of stage I 
ovarian cancer patients (Hoskins et al., 1992; Young et al., 1990). Although, the current 
diagnostic biomarker, CA125, can give an indication of the response to therapy, the disease 
progression and prognosis (Rustin et al., 1996), it has poor sensitivity especially for diagnosis of 
early-stage ovarian cancer (Havrilesky et al., 2008; Jacobs et al., 1993). Moreover, despite using 
a combination of biomarkers along with CA125 to increase its sensitivity in ovarian cancer 
diagnosis, survival rates did not improve significantly in the previous decades (Menon & Jacobs, 
2000). Here, we observed similar results with the blood CA125 levels, where 15% of patients in 
the study showed normal levels of blood CA125, despite being diagnosed with ovarian cancer. 
Therefore, new effective diagnostic markers are needed for early diagnosis of ovarian cancer to 
reduce ovarian cancer mortality rate.  
Circulating miRNAs are newly emerging potential diagnostic biomarkers. Being highly stable 
makes its measurement reproducible even after repeated freezing/thawing cycles or prolonged 
storage at room temperature. Several miRNAs showed to be differentially expressed in ovarian 
cancer, for instance miR-205, and let7 family. Nonetheless, similar expression patterns were 
observed in other cancer types, like let7-family that was downregulated in ovarian cancer as well 
as breast cancer. Also miR-205 was upregulated in ovarian cancer and it was also elevated in 
bladder and kidney cancer (Gottardo et al., 2007). On the other hand, miR-590-3p was found to 
be downregulated in bladder and kidney cancer, and to our knowledge, no work was done on 
miR-590-3p in ovarian cancer patients.  
To study the expression pattern of miR-590-3p in EOC, serum samples from EOC patients, EOC 
tissues, as well as control serum and ovarian tissues were collected. The clinical stage of the 
tumor was assessed according to the International Federation of Gynecology and Obstetrics 
(FIGO), and the tumor grade was pathologically determined. However, tumor tissues encompass 
heterogeneous population with different levels of tumor cell differentiation, which make it 
! 46!
challenging to correlate the expression of a molecular marker with that of the tumor histo-
pathological features. To overcome the intra-tumoral heterogeneity, we evaluated the histo-
pathological characteristics of the surgical specimens at the molecular level through examining 
acknowledged molecular biomarkers using RT-PCR. Thus, a single RNA aliquot is being 
examined for histo-pathological biomarkers, as well as the levels of miR-590-3p. We examined 
the mRNA steady-state levels of CA125/Mucin16 as a biomarker for ovarian cancer. We 
observed that the low levels of CA125 in blood reflected low expression levels of CA125 in the 
tumor tissues. CA125 levels were low in patients subjected to platinum-based combination 
chemotherapy, which is in agreement with prior studies that showed that CA125 levels reflect 
the ovarian carcinoma response to chemotherapy (Rustin et al., 1996). We used CRP as a 
biomarker for the clinical stage, and we observed elevated levels of CRP in advanced stages. 
PAX2, which is a biomarker for low-grade ovarian cancer, was only detected in low-grade EOC. 
Higher-grade EOC showed abolished expression of PAX2. In agreement with previous studies, 
PAX2 expression was not detected in the ovarian mucinous carcinoma specimen (Schaner et al., 
2003; Wang et al., 2015). Unexpectedly, we observed abolished PAX2 expression in six low-
grade ovarian serous carcinoma specimens. One possible explanation is the tissue heterogeneity 
and the different levels of cell differentiation within the samples. 
In the present study, we found that circulating miR-590-3p in the serum is a promising diagnostic 
biomarker for EOC. As we showed that circulating miR-590-3p levels were elevated in EOC 
patients compared to healthy females (Figure 8). Moreover, elevated miR-590-3p was not 
observed in the patient with benign ovarian tumor. Serum miR-590-3p was elevated in both early 
and late stages (Figure 9). Remarkably, miR-590-3p was elevated in stage-IB EOC patient with 
low pre-operative levels of serum CA125 (10U/ml).  Furthermore, the diagnostic ability of miR-
590-3p to distinguish between stage-I patients and healthy controls showed 75% sensitivity at its 
optimal cutoff value, which is higher than the previously reported sensitivity of CA125 at early 
stages. As the sensitivity of CA125 to discriminate between stage I/II ovarian cancer patients 
(n=133) and healthy controls (n=396) was only 45.9% (Havrilesky et al., 2008). Therefore, our 
results suggest that miR-590-3p is a promising diagnostic biomarker for early diagnosis of EOC.  
To study whether serum miR-590-3p reflects a dysregulation in EOC tissues, we examined the 
levels of miR-590-3p in the tumor tissues. Similarly, miR-590-3p was significantly upregulated 
in EOC relative to normal ovarian tissues (Figure 11). This observation is in accord with a 
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previous study that measured the ovarian cancer-derived exosomal miRNA content and its 
correlation with the ovarian tumor cellular miRNA and reported that the mature miR-590 was 
among the 175 miRNAs that exhibited equal levels in the tumor cells and the tumor-derived 
exosomes (Taylor et al., 2008). Our results suggest that the elevated serum miR-590-3p could be 
originated from the ovarian tumor cells, implying that it could be used for accurate diagnosis of 
ovarian cancer. 
We observed a high correlation between tissue miR-590-3p and the tumor grade. As, miR-590-
3p showed significant higher level in high-grade poorly-differentiated EOC relative to low-grade 
EOC (Figure 11). Its involvement in tumor cell differentiation is consistent with our 
bioinformatics analysis that predicted the role of miR-590-3p through analyzing the function of 
its down-stream target genes, which were significantly enriched in the cell differentiation 
processes. Similar expression pattern of miR-590-3p was previously reported in glioma that 
showed elevated levels of miR-590-3p in anaplastic gliomas and secondary glioblastomas 
relative to low-grade gliomas (Yan et al., 2014). The poorly differentiated EOC is usually 
associated with enhanced tumorigenic potential and aggressiveness (V. W. Chen et al., 2003; X. 
Chen et al., 2013; Vang et al., 2009). The elevated levels of miR-590-3p in poorly differentiated 
EOC urged us to examine the association of its levels with metastasis and EMT. Nonetheless, we 
were limited by the small sample size of cases with metastasis (n=3). Thus, there was no 
significant variation in miR-590-3p levels in the patients with metastasis and the EOC patients 
without metastasis. There is a current hypothesis that attempts to explain tumor progression, 
which suggest that tumor initiating cells can undergo epithelial to mesenchymal transition to 
reach a more advanced grade of differentiation (Heerboth et al., 2015). Therefore, EMT is crucial 
in ovarian cancer progression. This tumor progression does not necessarily imply that all the 
cells that underwent EMT will become metastatic (Sarkar et al., 2013). Therefore, we examined 
the mRNA steady-state levels of EMT-related markers, the epithelial marker E-cadherin, and the 
mesenchymal marker Vimentin, in EOC tissues to study the correlation between miR-590-3p and 
EMT in EOC. We observed that the mesenchymal marker Vimentin was elevated in EOC with 
high miR-590-3p levels relative to EOC tissues with relatively lower miR-590-3p and the control 
tissues (Figure 12). This observation indicates that miR-590-3p could be involved in the tumor 
progression and EMT. 
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The overexpression in EOC doesn’t necessarily imply that miR-590-3p is playing an oncogenic 
role. Therefore, to clarify the role of miR-590-3p in EOC, we used bioinformatics analysis to 
predict the potential target genes of miR-590-3p and to study their expression profiles in ovarian 
cancer through analyzing the cancer genome atlas (TCGA) ovarian cancer gene expression data 
and microarray datasets retrieved from previous studies. We examined the levels of three 
potential downstream targets, SOX2, LEF1 and PAX2 in selected EOC samples that represent the 
high miR-590-3p EOC and the low miR-590-3p EOC, as well as the control group. Our in silco 
analysis of the TCGA ovarian cancer gene expression data showed that SOX2 is downregulated 
in ovarian cancer relative to normal ovarian tissue (Figure 13). Nonetheless, SOX2 steady-state 
levels in EOC tissues at the RNA and protein levels did not show significant correlation between 
SOX2 and miR-590-3p levels (Figure 16). The negative correlation between LEF1 and miR-590-
3p expression that we observed from our in silco analysis of the ovarian cancer TCGA datasets 
using StarBase Pan-cancer analysis platform urged us to examine the levels of LEF1 in EOC 
(Figure 14). This negative correlation was not observed in the studied EOC tissues at the RNA or 
the protein level (Figure 17). This could be owing to the different approaches used in quantifying 
the expression levels and also the heterogeneity of the tissue samples. Therefore, further studies 
need to be conducted on relatively larger sample size. Also using ovarian cancer cell lines could 
serve as a homogenous model of ovarian cancer that could be utilized to examine the effect of 
miR-590-3p ectopic expression or knockdown on the expression of its potential downstream 
target genes. 
We observed that PAX2 expression was completely abolished in EOC samples with high miR-
590-3p levels, suggesting that it could be targeted by miR-590-3p (Figure 18). PAX2 is a nuclear 
transcription factor, whose expression is essential in embryonic development, cellular 
differentiation, and organogenesis. Altered PAX2 expression was observed in various cancer 
types, including ovarian cancer. Where, PAX2 exhibits high expression in low-grade and low 
malignant potential ovarian serous carcinoma, but low level of gene expression in high-grade 
ovarian serous carcinoma (Tung et al., 2009). PAX2 knockdown in PAX2-expressing ovarian 
cancer cell line (Tov21g malignant ovarian clear cell adenocarcinoma cell line) resulted in the 
reduction of cell proliferation and migration, suggesting an oncogenic role of PAX2. However, 
PAX2 ectopic expression in ovarian serous adenocarcinoma cell lines (OVCA-432 and OVCAR) 
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resulted in a reduction in cell proliferation, suggesting that PAX2 can act as an oncogene or 
tumor suppressor depending on the genetic basis of the tumor cells (Song et al., 2013). 
The elevated levels of miR-590-3p in poorly-differentiated EOC, the negative correlation 
between miR-590-3p and PAX2 expression, as well as the adoption of the EMT markers in the 
high miR-590-3p EOC, suggest that miR-590-3p could have a role in tumor development from 
healthy well-differentiated ovarian cell to dedifferentiate into poorly-differentiated tumor-
initiating cells. Also, our results that miR-590-3phigh/PAX2low signature is associated with poorly 
differentiated high-grade EOC could suggest another theory. Where the high-grade ovarian 
carcinoma with miR-590-3phigh/PAX2low could have developed from different pathway or origin 
than that of the low-grade ovarian carcinoma. These hypothetical models require further 
investigation. 
Moreover, through the analysis of the expression profiles of miRNAs available at The Cancer 
Genome Atlas (TCGA) Data Portal, we observed diverse expression patterns of miR-590-3p in 
different types of cancer (Figure 19). The discrepancy in miR-590-3p altered expression in 
cancer indicates that it could exhibit both tumor suppressor and oncogenic role depending on the 
genetic basis of the tumor cells that could be defined by the tumor origin and the stage of tumor 
progression. Therefore, more studies are still required to clarify the role of miR-590-3p in 
carcinogenesis. We were limited by not examining the levels of the potential downstream targets 
in all the samples and not examining the protein levels of PAX2. The direct binding of miR-590-
3p to the 3’UTR of PAX2 needs to be examined to confirm the direct regulation. We were also 
limited by the relatively small sample size. Also, further studies need to be conducted in cultured 
ovarian cancer cells to serve as a more homogenous model of ovarian cancer. As the tumor 
tissues comprise a highly heterogeneous population with different stages of tumor cell 
differentiation, which heighten the complexity in studying the role of miR-590-3p and its 
potential downstream targets in EOC carcinogenesis.  
In conclusion, we have shown that circulating miR-590-3p is a promising diagnostic biomarker 
for early detection of epithelial ovarian cancer.  Nonetheless, further studies need to be 
conducted on larger sample size. Our result of miR-590-3p levels in the serum is a step forward 
towards developing an approach for early-stage ovarian cancer detection. We showed that miR-
590-3p was elevated in EOC tissues, with enhanced expression in high-grade poorly 
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differentiated tumors. The high miR-590-3p levels in EOC were associated with the adoption of 
EMT markers and abolished PAX2 expression. The role of miRNAs expression in the 
progression of tumor initiating cells from normal well-differentiated cells is still unknown. The 
expression pattern of miR-590-3p in EOC tissues, as well as its in silco predicted downstream 
targets that were enriched in the cell differentiation processes, suggest that miR-590-3p could 
have a role in the tumor initiation stage.  
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Appendix A: Real time PCR Amplification Plot 
 
Appendix A Figure: Real-time PCR amplification plot for the serum and tissue samples. 
The real-time PCR experiment was performed to quantify the levels of miR-590-3p, as well as 
the spike-in control Cel_miR-39-3P miRNA mimic in the serum samples and the endogenous 
control U6 snRNA in the tissue samples. The amplification plot displays the change of 
fluorescence (y-axis) during PCR cycling (x-axis). Individual curves are grouped into similar 
quantified concentrations by color. 
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    Appendix B: Quantitative Real-Time RT-PCR 
Comparative CT Analysis  
Serum Samples 
   
       
       
           
Average Normal Serum 
Normalized Ct value= 33.8        
Median Spike-In control Ct 
value = 24.235        
           
Sample 
MiR-590-
3p 
Avg. CT 
Std. 
Dev. 
Spike-
In 
control 
Avg. 
CT 
Std. 
Dev. 
Normalization 
Factor 
Median 
normalized ΔCT  
(miR-590-3p + 
Normalization 
factor) 
Std. 
Dev. 
ΔΔCT= 
(ΔCT Cancer 
–average 
ΔCT normal) 
Std. 
Dev. 
MiR-590-
3p 
Relative 
to Avg. 
Normal 
(2- ΔΔCT) 
Fold 
Change 
Relative 
to Normal 
Log10 
(2- ΔΔCT) 
NS1 35.75   24.09                   
  34.6   23.69                   
  35.18 0.81 23.89 0.28 0.34 35.52 0.86 1.72 0.86 0.30 -3.30 -0.52 
             NS2 33.15   20.4                   
  32.52   20.66                   
  32.84 0.45 20.53 0.18 3.71 36.54 0.48 2.74 0.48 0.15 -6.69 -0.83 
             NS3 30.49   23.19                   
  30.54   22.94                   
  30.52 0.04 23.07 0.18 1.17 31.69 0.18 -2.11 0.18 4.32 4.32 0.64 
             NS4 33.56   25.11                   
  33.39   24.76                   
  33.48 0.12 24.94 0.25 -0.70 32.78 0.28 -1.02 0.28 2.03 2.03 0.31 
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             NS5 33.73   23.2                   
  33.87   23.05                   
  33.80 0.10 23.13 0.11 1.11 34.91 0.15 1.11 0.15 0.46 -2.16 -0.34 
             NS6 34.39   24.44                   
  33.41   24.72                   
  33.90 0.69 24.58 0.20 -0.34 33.56 0.72 -0.24 0.72 1.18 1.18 0.07 
             BS1 32.86   25.31                   
  32.22   25.05                   
  32.54 0.45 25.18 0.18 -0.95 31.60 0.49 -2.20 0.49 4.60 4.60 0.66 
             CS1 32   24.36                   
  32.54   24.01                   
  32.27 0.38 24.19 0.25 0.05 32.32 0.46 -1.48 0.46 2.78 2.78 0.44 
             CS2 27.53   21.99                   
  26.84   21.05                   
  27.19 0.49 21.52 0.66 2.72 29.90 0.82 -3.90 0.82 14.90 14.90 1.17 
             CS9 24.3   22.92                   
  24.78   22.45                   
  24.54 0.34 22.69 0.33 1.55 26.09 0.48 -7.71 0.48 208.97 208.97 2.32 
             CS10 19.87   21.36                   
  20.52   21.37                   
  20.20 0.46 21.37 0.01 2.87 23.07 0.46 -10.73 0.46 1700.97 1700.97 3.23 
             CS11 30.4   23.06                   
  29.72   21.18                   
  30.06 0.48 22.12 1.33 2.12 32.18 1.41 -1.62 1.41 3.08 3.08 0.49 
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             CS12 28.86   25.52                   
  29.28   25                   
  29.07 0.30 25.26 0.37 -1.03 28.05 0.47 -5.75 0.47 53.90 53.90 1.73 
             CS13 34.37   26.23                   
  34.82   25.87                   
  34.60 0.32 26.05 0.25 -1.82 32.78 0.41 -1.02 0.41 2.02 2.02 0.31 
             CS14 33.11   25.08                   
  32.93   24.99                   
  33.02 0.13 25.04 0.06 -0.80 32.22 0.14 -1.58 0.14 2.98 2.98 0.47 
             CS15 23.39   25.98                   
  24.2   25.76                   
  23.80 0.57 25.87 0.16 -1.64 22.16 0.59 -11.64 0.59 3185.14 70.00 3.50 
             CS16 29.83   32                   
  29.9   33.67                   
  29.87 0.05 32.84 1.18 -8.60 21.27 1.18 -12.53 1.18 5923.13 5923.13 3.77 
             CS17 29.55   29.9                   
  32.36   29.9                   
  30.96 1.99 29.90 0.00 -5.67 25.29 1.99 -8.51 1.99 363.84 363.84 2.56 
             CS18 34.92   19.02                   
  32.69   19.69                   
  33.81 1.58 19.36 0.47 4.88 38.69 1.65 4.89 1.65 0.03 -29.61 -1.47 
             CS19 31.37   20.21                   
  31.86   18.91                   
  31.62 0.35 19.56 0.92 4.68 36.29 0.98 2.49 0.98 0.18 -5.63 -0.75 
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!!!
Appendix C: Quantitative Real-Time RT-PCR  
Comparative CT Analysis  
Tissue samples !
 
 Average Normal Normalized Ct value = 9.11 
    
            
Sample 
MiR-590-
3p Avg. 
CT 
Std. 
Dev. 
U6 snRNA 
Avg. CT 
Std.
Dev. 
ΔCT  
(MiR-590-3p – 
(U6snRNA) 
Std.
Dev. 
ΔΔCT= 
(ΔCT Cancer – 
average ΔCT 
normal) 
Std.
Dev. 
MiR-590-3p 
Relative to Avg. 
Normal 
(2- ΔΔCT) 
Fold 
Change 
Relative to 
Normal 
Log10 (2- ΔΔCT) 
N1 31.81   21.65                 
  31.89   22.53                 
  29.93   20.9                 
  29.08   20.82                 
  30.68 1.40 21.48 0.80 9.20 1.61 0.09 1.61 0.9403 -1.06 -0.03 
            N2 30.59   21.84                 
  29.19   21.33                 
  29.89 0.99 21.59 0.36 8.31 1.05 -0.81 1.05 1.7517 1.75 0.24 
            N3 30.69   21.17                 
  29.22   20.69                 
  29.96 1.04 20.93 0.34 9.03 1.09 -0.09 1.09 1.0634 1.06 0.03 
            N4 29.49   15.61                 
  29.83   18.21                 
  29.66 0.24 16.91 1.84 12.75 1.85 3.64 1.85 0.0804 -12.43 -1.09 
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N5 28.58   19.26                 
  28.51   19.26                 
  28.55 0.05 19.26 0.00 9.29 0.05 0.17 0.05 0.8881 -1.13 -0.05 
            N6 24.93   18.62                 
  25.15   16.37                 
  25.04 0.16 17.50 1.59 7.55 1.60 -1.57 1.60 2.9665 2.97 0.47 
            B1 26.12   17.19                 
  26.06   17.52                 
  26.09 0.04 17.36 0.23 8.74 0.24 -0.38 0.24 1.3002 1.30 0.11 
            C1 32.68   24.73                 
  35.02   20.23                 
  29.76   20.92                 
  29.38   20.55                 
  33.85 1.65 22.48 3.18 11.37 3.59 2.26 3.59 0.2093 -4.78 -0.68 
            C2 31.5   24.7                 
  29.65   27.5                 
  30.58 1.31 26.10 1.98 4.48 2.37 -4.64 2.37 24.9117 24.91 1.40 
            C3 34.92   21.58                 
  33.9   21.12                 
  34.41 0.72 21.35 0.33 13.06 0.79 3.95 0.79 0.0649 -15.41 -1.19 
            C4 29.22   22.39                 
  29.85   22.47                 
  29.54 0.45 22.43 0.06 7.11 0.45 -2.01 0.45 4.0243 4.02 0.60 
            C5 32.42   21.14                 
  30.28   22.96                 
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  31.35 1.51 22.05 1.29 9.30 1.99 0.19 1.99 0.8789 -1.14 -0.06 
            
            C6 29.8   21.2                 
  28.87   21.67                 
  29.34 0.66 21.44 0.33 7.90 0.74 -1.21 0.74 2.3194 2.32 0.37 
            C7 25.75   18.09                 
  25.69   18.63                 
  25.72 0.04 18.36 0.38 7.36 0.38 -1.75 0.38 3.3723 3.37 0.53 
            C8 24.62   20.13                 
  24.87   20.89                 
  24.75 0.18 20.51 0.54 4.24 0.57 -4.88 0.57 29.4205 29.42 1.47 
            C9 27.78   21.02                 
  28.3   21                 
  28.04 0.37 21.01 0.01 7.03 0.37 -2.08 0.37 4.2391 4.24 0.63 
            C10 24.69   18.87                 
  24.81   18.5                 
  24.75 0.08 18.69 0.26 6.07 0.28 -3.05 0.28 8.2749 8.27 0.92 
            C11 26.71   20.92                 
  26.91   21.47                 
  26.81 0.14 21.20 0.39 5.62 0.41 -3.50 0.41 11.3039 11.30 1.05 
            C12 26.82   19.87                 
  26.68   19.49                 
  26.75 0.10 19.68 0.27 7.07 0.29 -2.04 0.29 4.1232 4.12 0.62 
            C13 27.15   22.41                 
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  27.26   21.34                 
  27.21 0.08 21.88 0.76 5.33 0.76 -3.78 0.76 13.7728 13.77 1.14 
            C14 29.01   19.45                 
  30.75   19.45                 
  29.88 1.23 19.45 0.00 10.43 1.23 1.32 1.23 0.4016 -2.49 -0.40 
            C15 25.43   19.87                 
  25.41   19.73                 
  25.42 0.01 19.80 0.10 5.62 0.10 -3.49 0.10 11.2648 11.26 1.05 
            C16 28.7   21.71                 
  28.71   21.97                 
  28.71 0.01 21.84 0.18 6.87 0.18 -2.25 0.18 4.7527 4.75 0.68 !
C17 26.9   18.56                 
  25.87   18.06                 
  26.39 0.73 18.31 0.35 8.08 0.81 -1.04 0.81 2.0544 2.05 0.31 
            C18 24.43   18.42                 
  25.52   18.35                 
  24.98 0.77 18.39 0.05 6.59 0.77 -2.52 0.77 5.7507 5.75 0.76 
            C19 23.18   16.41                 
  22.92   17.01                 
  23.05 0.18 16.71 0.42 6.34 0.46 -2.77 0.46 6.8388 6.84 0.83 
            C20 28.11   18.62                 
  27.26   18.74                 
  27.69 0.60 18.68 0.08 9.01 0.61 -0.11 0.61 1.0783 1.08 0.03 
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Appendix E: Patient’s Consent Forms 
!
Documentation!of!Informed!Consent!for!Participation!in!Research!Study!
!
Project!Title:!The!expression!pattern!of!miRNA659063P!in!epithelial!ovarian!cancer!is!a!potential!diagnostic!biomarker!for!ovarian!cancer!early!diagnosis.!!
Principal!Investigator:!Heba!Shawer.!Biotechnology!Program,!American!University!in!Cairo,!New!Cairo,!11835!Egypt!E6mail:!Hebashawer@aucegypt.edu.!!*You!are!being!asked!to!participate!in!a!research!study.!!The!purpose!of!the!research!is!to!study!the!expression!of!certain!molecule!in!ovarian!cancer!tissue!samples.!The!Successful!completion!of!this!project!could!provide!better!explanation!to!the!genetic!background!of!the!disease,!and!the!potential!gene!therapies.!!!The!findings!of!the!study!may!be!published!and/or!presented!in!conferences.!!The!expected!duration!of!the!study!is!one!year.!On!completion!of!the!thesis,!the!data!will!be!retained!for!a!further!six!months,!and!then!destroyed.!!*The!procedures!of!the!research!will!be!as!follows:!The!level!of!certain!molecule!will!be!analyzed!in!ovarian!cancer!tissues!and!in!the!patient’s!blood!samples!using!real!time!polymerase!chain!reaction!(RT6PCR)!method.!This!molecule!in!the!patients’!serum!will!be!examined!to!evaluate!the!possibility!to!be!used!as!a!biomarker!and!whether!it!can!give!indication!for!the!tumor!stages.!!*There!will$not$be!any!risks!or!discomforts!associated!with!this!research.!As,!nothing!will!be!taken!for!research!purpose!only.!The!specimens!will!not!be!collected!specifically!for!the!research!project!.We!will!only!use!portion!of!the!samples!that!are!collected!for!medical!purpose.!!!*There!will$not$be!benefits!to!you!from!this!research.!However,!you!will!make!a!chief!contribution!to!develop!the!information!known!about!ovarian!cancer.!!*The!information!you!provide!for!purposes!of!this!research!is$anonymous.!This!information!will!be!kept!in!a!password6protected!personal!laptop.!Only!the!principle!investigator!of!the!study,!the!thesis!advisor!and!the!surgeon!providing!us!with!the!samples!will!have!access!to!the!research!data.!No!clues!to!your!identity!appear!in!the!thesis;!your!identity!in!the!thesis!or!any!research!paper!will!be!entirely!anonymous.!!
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Questions!about!the!research,!my!rights,!or!research6related!injuries!should!be!directed!to!Heba!Shawer.!!*Participation!in!this!study!is!voluntary.!Refusal!to!participate!will!involve!no!penalty!or!loss!of!benefits!to!which!you!are!otherwise!entitled.!You!may!discontinue!participation!at!any!time!without!penalty!or!the!loss!of!benefits!to!which!you!are!otherwise!entitled.!Signature!! ! ________________________________________!Printed!Name!! ________________________________________!Date! ! ! ________________________________________!!!!!!!!!!!!!!!!!!!!!!!
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!! ! )('سة بحث"ة للمشا%كة في مسبقة $ستما(' مو$فقة
في سر4ا3 &لمب(ض &لظا/ر. في &لتشخ(ص &لمبكر  10&سة &مكان,ة &ستخد&% مركبعنو%& %لبحث : 
! ! لسر)ا' &لمب"ض.
! #بة محمو9 شا76. 5البة ماجست)ر بالجامعة .لامر+ك)ة بالقا#ر!.'لباحث 'لرئ#سي: 
! ude.tpygecua@rewahsabeh)لبر+د )لالكتر#ني: 
! ! %!٤%$#"!!"!&ل$اتف: 
'لمب"ض ( 'مكان"!  بحث)ة عن 1جو. مركب مع)ن في سر#ا!  #نت مدعو للمشا$كة فى %$#سة
!لنجا< في !لانت7اء من 2ذ! !لمشر-, قد )وفر تفس#ر!  &ستخد&م3 في &لتشخ"ص &لمبكر لسر)ا' &لمب"ض.
  لف)! 'لج)ن)ة للمر2 1 'لعلاجا, 'لج)ن)ة 'لمحتمل!. 'فضل للخ
 
  تشخ"ص &لمبكر لسر)ا' &لمب"ض.-لوصو+ لوس(لة جد%د# لل"و (د' #لد$#سة  
 
! ! . ص1 *) مؤتمر علمي *) (بما كل$#ما)('&% متخصستنشر فى نتائج %لبحث  
سة- سو* )تم 'لاحتفا! بعد !لانت)اء من !لد"!للمشا3كة فى *ذ$ $لبحث *ي سنة %$حد!.  (لمد) (لمتوقعة
! بالب8انا6 لمد3 ستة *ش"ر *خر- ثم *لتخلص من"ا.
 
ء من /لو:9 /لذ7 /ستاصل3 /لجر/. لاسبا+ *ب(ة. سو% تكو! '&%سة جز علي تشتمل#جر#ء#' #لد$#سة 
  .مؤتمر علمي "! "! 1و.ة #لمر.ض مج*ولة في #لد$#سة
 
لا1 #لع(نا. لن تؤخذ خص(صا من #جل  من 'لمشا(كة فى ,ذ* 'لد('سة. $#لك متوقعةمخا"ر  $وجد لا
!  &لدG&سة &لبحث"ة. سوB نستخد> فقد جزء من &لع"نا3 &لتي تم &خذ+ا لاغر&% $ب"ة.
قد لا توجد ,ستفا54 شخص0ة من ,لبحث. ( لكن$ سو! %لاستفا54 %لمتوقعة من  %لمشا*كة في %لبحث: 
!  7س;م في 87ا65 &لمعرفة &لمعلومات"ة  عن سر)ا' &لمب"ض.
غ"ر  %و#تكف#"ا  B+حتر+? +لخصوص;ة: +لمعلوما5 +لتى ستدلى ب1ا فى -ذ+ +لبحث سو% تكو! &لسر"ة
. + سوE تحفظ Bذ@ ?لمعلوما= في ج"ا: كمب#وتر محمي بكلمة مر+/ سر(ة + لن (طلع عل#"ا محد"! 
ستكو) (و&تك غ"ر  سو- /لباحث /لرئ$سي * /لمشر9 علي /لبحث * /لجر/0 /لذ- ,ز*)نا بالع$نا!. 
! خا' بالبحث. مؤتمر علمي "!ص# "!)('&% متخصفي "! "! محد
 
0G 0سئلة متعلقة ب6ذ! .لد:.سة 02 حقو> .لمشا:ك7ن ف76ا 02عند حد21 0/  .صابا+ ناتجة عن #ذ!  
! مو% شا"!.%بة مح#لمشا.كة +جب #( توج$ #لى 
!17 !
!
لا'تضمن "! (0 (لمشا#كة فى :ذ= (لد#(سة ما:ى (لا عمل تطوعى, ح3ث 10 (لامتنا+ عن (لمشا#كة 
عقوباD .' فقد7& .- مز7;ا تحق لك. ';مكنك .;ضا 7لتوقف عن 7لمشا2كة فى .- 'قت من ('& عقوبة 
! ! /. فقد#* ل)ذ' #لمز#"ا. 
! ! &لامضاء: ..........................................................
! ! 'سم 'لمشا"! : ...................................................
! 'لتا#"خ : ........./................/..............
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